Authors


Erin Johanek, PharmD, RPh

Latest:

Popular insulin meets target in real-world study

Novo Nordisk’s DEVOTE study reveals interesting findings.


Ramesh Upadhyayula, RPh

Latest:

Experience Brief: Desert Hospital Outpatient Pharmacy partnering with hospital to reduce readmissions among CHF patients

Desert Hospital Outpatient Pharmacy is an independent pharmacy inside Desert Regional Medical Center, a 387-bed tertiary acute care hospital located in Palm Springs, California. Desert Regional Medical Center, which has attained the Joint Commission’s Gold Seal of Approval for its congestive heart failure program, has reduced readmission rates by 17% among congestive heart failure (CHF) patients through a close partnership with Desert Hospital Outpatient Pharmacy.


Moses S.S. Chow, PharmD, FCP, FCCP

Latest:

Pharmacologic treatment of prostate cancer

Prostate cancer is the most frequently diagnosed cancer, aside from non-melanoma skin cancer, in men in the United States. According to the American Cancer Society, an estimated 233,000 new cases of prostate cancer and an estimated 29,480 deaths from prostate cancer will have occurred in the United States during 2014. About 60% of all prostate cancer cases are diagnosed in men aged 65 years and older, and 97% of cases occur in men aged 50 and older. The incidence of prostate cancer is 60% higher in African Americans than in whites.


Doreen Pon, PharmD, BCOP, BCP

Latest:

Pharmacologic treatment of prostate cancer

Prostate cancer is the most frequently diagnosed cancer, aside from non-melanoma skin cancer, in men in the United States. According to the American Cancer Society, an estimated 233,000 new cases of prostate cancer and an estimated 29,480 deaths from prostate cancer will have occurred in the United States during 2014. About 60% of all prostate cancer cases are diagnosed in men aged 65 years and older, and 97% of cases occur in men aged 50 and older. The incidence of prostate cancer is 60% higher in African Americans than in whites.


Zhi Jun Wang, Ph.D.

Latest:

Pharmacologic treatment of prostate cancer

Prostate cancer is the most frequently diagnosed cancer, aside from non-melanoma skin cancer, in men in the United States. According to the American Cancer Society, an estimated 233,000 new cases of prostate cancer and an estimated 29,480 deaths from prostate cancer will have occurred in the United States during 2014. About 60% of all prostate cancer cases are diagnosed in men aged 65 years and older, and 97% of cases occur in men aged 50 and older. The incidence of prostate cancer is 60% higher in African Americans than in whites.


Ellie Goldstein, MD

Latest:

BLOG: Time to show and tell about antibiotic stewardship programs

President Obama’s recent proposal to nearly double funding for antibiotic resistance programs to $1.2 billion in the 2016 federal budget confirms that the battle against “superbugs” is indeed moving up the government agenda.


Kristine Rawlings, PharmD

Latest:

Drugs in Perspective: Lemtrada (alemtuzumab)

Lemtrada (alemtuzumab) received FDA approval on November 14, 2014, under fast track designation, for the treatment of patients with relapsing forms of MS.Due to the safety profile, alemtuzumab should generally be reserved for patients who have had an inadequate response to 2 or more drugs indicated for MS.


Alpesh Amin, MD, MBA, MACP, SFHM

Latest:

[BLOG]: Best Practices between formulary managers and pharmacists to address challenges in COPD readmissions

To address the burden of COPD on hospital expenditures, on October 1, 2014, the Centers for Medicare & Medicaid Services included COPD in its Hospital Readmissions Reductions Program. This inclusion resulted in reduced Medicare reimbursement for hospitals that demonstrate excessive 30-day COPD patient readmission rates.


Gina McKnight-Smith, Pharm D, MBA, CGP, BCPS, CHTS-CP

Latest:

Drugs in Perspective: Opdivo (nivolumab)

On December 22, 2014, Opdivo (nivolumab) was approved by FDA with a breakthrough therapy designation. Nivolumab is the second human programmed death-1 (PD-1) receptor-blocking antibody to gain accelerated approval for treatment of patients with unresectable or metastatic melanoma and disease progression following Yervoy (ipilimumab) and, if BRAF V600 mutation positive, a BRAF inhibitor.


Katie Noon

Latest:

[BLOG]: 741 drugs in antibiotics pipeline, few first-in-class

Antibiotic resistance has grown at an alarming rate over the last few decades. To prevent a post-antibiotic era in which common infections could become lethal, an estimated 20 novel families of antibiotics must be developed in the next 50 years. Political groups in both the U.S. and Europe are each working to promote new development, but there are concerns the results may not come in time.








Andrea Marks, MS

Latest:

[BLOG]: Use and abuse of opioids: FDA responds

In this blog post, David Calabrese RPh, MHP and Andrea Marks, MS discuss Catamaran's research on opioid abuse. Catamaran is concerned about opioid misuse and is moving forward with plans to combat opioid abuse.


Robert Kyle

Latest:

[BLOG]: Obesity drug safety review

In this blog post, Robert Kyle of AdverseEvents compares the results of a postmarket survey of 3 obesity drugs.


David Gortler, PharmD, FCCP

Latest:

Major safety concerns with top-selling prescription drugs

Major safety concerns exist for many top-selling prescription drugs including benzodiazepines/prescription sleep aids, anticoagulants, cholesterol-lowering statins, oxycodone and hydrocodone, and stimulants. The following provides an overview of these classes and issues.


Heather Leach, PhD

Latest:

Parkinson’s disease: Unmet needs to be fulfilled by novel therapies and reformulations

The current global Parkinson’s disease market is characterized by a number of unmet needs, which include addressing the motor complications of dyskinesia and off-episodes. The recent approval of novel therapies and reformulations of existing drugs has the potential to fulfill some of these unmet needs, particularly in patients with advanced disease.


Louis Tharp

Latest:

[BLOG]: 5 reasons biosimilars must have distinguishable names

In this blog response to the July 13 article "5 reasons to keep biosimilar names the same," Louis Tharp, executive director or Global Healthy Living Foundation, lists 5 reasons biosimilars must have distinguishable names.


Juliana Reed

Latest:

[BLOG]: 5 things you need to know about biosimilars

The first biosimilar product was approved this spring. Pharmacists will want to familiarize themselves with this new class of therapies. Below are the five top things that a pharmacist should know about biosimilars.


Sam Abdelghany, PharmD, BCOP

Latest:

Carflizomib: A second-generation proteasome inhibitor for the treatment of myeloma

The introduction of the immunomodulatory drugs and bortezomib, a proteasome inhibitor, has dramatically improved outcomes in patients with relapsed or refractory multiple myeloma.


Christine Blank

Latest:

New Pediatric Growth Hormone Therapy Costs $8,300 Monthly

Longer-acting growth hormone reduces frequency of injections. It will be available in August.


Tracey Walker

Latest:

Study: 4F-PCC may be beneficial over plasma in patients needing warfarin reversal for urgent surgical, invasive procedures

Prothrombin Complex Concentrate [Human] (Kcentra) is non-inferior and superior to plasma for rapid international normalized ratio (INR) reversal and effective hemostasis in patients needing Vitamin K antagonist (VKA, eg, warfarin) reversal for urgent surgical or invasive procedures, according to a study published in The Lancet. INR is a standardized method of assessing the effects of VKA therapy commonly used by clinicians


From staff reports

Latest:

New online tool available for Janssen products

Janssen Pharmaceuticals, Inc. is making it easier for pharmacists and healthcare professionals to look up drug information by launching an online scientific resource tool.


Formulary staff

Latest:

FDA Grants Priority Review for Glofitamab for Blood Cancer

Genentech’s glofitamab is a bispecific antibody being reviewed to treat adults with large B-cell lymphoma. The FDA is expected to make a decision on approval by July 1, 2023.


Rocsanna Namdar, PharmD, BCPS

Latest:

Development of an adverse drug reaction bulletin in a teaching hospital

Bulletins that focus on drugs and therapeutic matters are often distributed by hospitals and other health systems that have programs for reporting adverse drug reactions.


Fanak Fahimi, PharmD, BCPS

Latest:

Development of an adverse drug reaction bulletin in a teaching hospital

Bulletins that focus on drugs and therapeutic matters are often distributed by hospitals and other health systems that have programs for reporting adverse drug reactions.


Shadi Baniasadi, PharmD, PhD

Latest:

Development of an adverse drug reaction bulletin in a teaching hospital

Bulletins that focus on drugs and therapeutic matters are often distributed by hospitals and other health systems that have programs for reporting adverse drug reactions.

© 2024 MJH Life Sciences

All rights reserved.